Abstract:Iron is required for most forms of organisms, and it is the most essential element for the functions of many iron-containing proteins involved in oxygen transport, cellular respiration, DNA replication, and so on. Disorders of iron metabolism are associated with diverse diseases, including anemias (e.g., iron-deficiency anemia and anemia of chronic diseases) and iron overload diseases, such as hereditary hemochromatosis and beta-thalassemia. Hepcidin (encoded by Hamp gene) is a peptide hormone synthesized by hepatocytes, and it plays an important role in regulating the systematic iron homeostasis. As the systemic iron regulator, hepcidin, not only controls dietary iron absorption and iron egress out of iron storage cells, but also induces iron redistribution in various organs. Deregulated hepcidin is often seen in a variety of iron-related diseases including anemias and iron overload disorders. In the case of iron overload disorders (e.g., hereditary hemochromatosis and beta-thalassemia), hepatic hepcidin concentration is significantly reduced.Since hepcidin deregulation is responsible for iron disorder-associated diseases, the purpose of this review is to summarize the recent findings on therapeutics targeting hepcidin.Continuous efforts have been made to search for hepcidin mimics and chemical compounds that could be used to increase hepcidin level. Here, a literature search was conducted in PubMed, and research papers relevant to hepcidin regulation or hepcidin-centered therapeutic work were reviewed. On the basis of literature search, we recapitulated recent findings on therapeutic studies targeting hepcidin, including agonists and antagonists to modulate hepcidin expression or its downstream signaling. We also discussed the molecular mechanisms by which hepcidin level and iron metabolism are modulated.Elevating hepcidin concentration is an optimal strategy to ameliorate iron overload diseases, and also to relieve beta-thalassemia phenotypes by improving ineffective erythropoiesis. Relative to the current conventional therapies, such as phlebotomy and blood transfusion, therapeutics targeting hepcidin would open a new avenue for treatment of iron-related diseases.

Non-reducible Disulfide Bond Replacement Implies That Disulfide Exchange is Not Required for Hepcidin-Ferroportin Interaction.

Advance in Hepcidin

Cilia Control Fat Deposition during Tissue Repair.

Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis

Dynamics of Thiol/Disulfide Exchange Within a Single Protein

An Intramolecular Disulfide Bond Designed in Myoglobin Fine-Tunes Both Protein Structure and Peroxidase Activity.

Diaminodiacid Bridges to Improve Folding and Tune the Bioactivity of Disulfide‐Rich Peptides

Structural Basis of Ion Transport and Inhibition in Ferroportin

Synthetic Porcine Hepcidin Exhibits Different Roles in Escherichia Coli and Salmonella Infections

A Role of PDI in the Reductive Cleavage of Mixed Disulfides.

Structural and Biochemical Characterization of Silver/Copper Binding by Dendrorhynchus zhejiangensis Ferritin

Neutral Thiol As A Proximal Ligand to Ferrous Heme Iron: Implications for Heme Proteins That Lose Cysteine Thiolate Ligation on Reduction

HDAC1 Governs Iron Homeostasis Independent of Histone Deacetylation in Iron-Overload Murine Models

Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review.

Hephaestin is A Ferroxidase That Maintains Partial Activity in Sex-Linked Anemia Mice

The hepcidin-ferroportin axis modulates liver endothelial cell BMP expression to influence iron homeostasis in mice

Regulation of Both the Structure and Function by a De Novo Designed Disulfide Bond: a Case Study of Heme Proteins in Myoglobin

An essential cell-autonomous role for hepcidin in cardiac iron homeostasis

Iron absorption in hepcidin1 knockout mice

Iron regulation of hepcidin despite attenuated Smad1,5,8 signaling in mice without transferrin receptor 2 or Hfe.

Exploring the Influence of Zinc Ions on the Conformational Stability and Activity of Protein Disulfide Isomerase